CLINICAL_TRIALS
trial_result
· 2017-05-25
Clinical Trial Update: Amgen 386 for Recurrent Glioblastoma [Phase 1, Phase 2]
Summary
Clinical trial update reports completion of Amgen's AMG-386 studies in recurrent glioblastoma (Phase 1/2) with results posted in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dana-Farber Cancer Institute | Conditions: Glioblastoma Multiforme | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-05-25